415 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 415 shares of the company’s stock, valued at approximately $230,000.

Other large investors have also made changes to their positions in the company. Patron Partners LLC boosted its holdings in shares of IDEXX Laboratories by 2.7% during the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock valued at $425,000 after purchasing an additional 20 shares during the last quarter. NewEdge Wealth LLC lifted its position in shares of IDEXX Laboratories by 3.1% in the fourth quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock worth $366,000 after buying an additional 20 shares in the last quarter. Phoenix Holdings Ltd. boosted its stake in IDEXX Laboratories by 2.8% during the third quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock valued at $338,000 after buying an additional 21 shares during the last quarter. BluePath Capital Management LLC grew its holdings in IDEXX Laboratories by 1.8% during the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock valued at $663,000 after buying an additional 21 shares in the last quarter. Finally, Valley National Advisers Inc. increased its stake in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after acquiring an additional 22 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent research reports. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Barclays decreased their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Finally, The Goldman Sachs Group upped their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $580.88.

IDEXX Laboratories Stock Up 2.8 %

Shares of NASDAQ:IDXX opened at $500.82 on Friday. The firm has a market capitalization of $41.36 billion, a PE ratio of 48.48, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. The business has a 50 day simple moving average of $517.91 and a two-hundred day simple moving average of $514.15. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same quarter in the previous year, the business earned $2.05 EPS. IDEXX Laboratories’s revenue was up 8.8% compared to the same quarter last year. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.05 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.